IRWD News and Press, Ironwood Pharmaceuticals Inc. From 10/27/23

2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 9, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada)...

– Data reinforce the impact of linaclotide on symptoms of IBS-C and CIC – – Additional studies highlight the burden of these disorders on patients – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, present...

– Data show approximately 50% reduction of parenteral support (PS) volume – – 100% of patients were clinical responders – – 78% of patients achieved one or more days off PS – – Results support apraglutide as a potentiall...

– Data demonstrates that linaclotide reduces the need for rescue medications in this patient population – – Additional presentations further characterize the efficacy and safety profiles of linaclotide as the only FDA-approved prescription therapy for this patient pop...

2023-09-28 12:52:41 ET More on Ironwood Pharmaceuticals Ironwood: Pipeline Progresses As FDA Approves LINZESS Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Ironwood Pharmaceuticals Historical ear...

2023-09-19 11:18:41 ET More on Ironwood Pharmaceuticals Ironwood: Pipeline Progresses As FDA Approves LINZESS Seeking Alpha's Quant Rating on Ironwood Pharmaceuticals Historical earnings data for Ironwood Pharmaceuticals Financial information for Ironwood Pha...

2023-08-08 11:26:07 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2023 Earnings Call Transcript August 08, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Sravan Emany - Chief Financial Office...

2023-08-08 07:25:44 ET Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q2 Non-GAAP EPS of -$6.71 misses by $6.96 . Revenue of $107.38M (+10.4% Y/Y) beats by $3.66M . Ironwood is increasing its 2023 U.S. LINZESS net sales and total revenue growth guidan...

– LINZESS (Iinaclotide) EUTRx prescription demand growth increased 9% year-over-year; LINZESS U.S. net sales of $270 million, an increase of 9% year-over-year – – Expands clinical utility of LINZESS with FDA approval for pediatric patients ages 6-17 years-old sufferin...